GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Earnings per Share (Diluted)

SNNAQ (Sienna Biopharmaceuticals) Earnings per Share (Diluted) : $-2.00 (TTM As of Sep. 2019)


View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Earnings per Share (Diluted)?

Sienna Biopharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2019 was $-0.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.00.

Sienna Biopharmaceuticals's EPS (Basic) for the three months ended in Sep. 2019 was $-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.00.

Sienna Biopharmaceuticals's EPS without NRI for the three months ended in Sep. 2019 was $-0.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.02.


Sienna Biopharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Sienna Biopharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Earnings per Share (Diluted) Chart

Sienna Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18
Earnings per Share (Diluted)
-0.99 -1.86 -5.19 -3.59

Sienna Biopharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 -0.93 -0.67 -0.27 -0.13

Competitive Comparison of Sienna Biopharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Sienna Biopharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sienna Biopharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sienna Biopharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sienna Biopharmaceuticals's PE Ratio falls into.



Sienna Biopharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Sienna Biopharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2018 is calculated as

Diluted Earnings Per Share (A: Dec. 2018 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-73.471-0)/20.450
=-3.59

Sienna Biopharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2019 is calculated as

Diluted Earnings Per Share (Q: Sep. 2019 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-3.97-0)/30.726
=-0.13

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Sienna Biopharmaceuticals  (OTCPK:SNNAQ) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sienna Biopharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sienna Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.
Executives
Alexander Azoy officer: Chief Financial Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews officer: General Counsel & Secretary 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield director, officer: President & CEO C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann officer: See Remarks 30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton director
Todd Harris director 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Sienna Biopharmaceuticals Headlines